ACE and diabetes mellitus: The TRANSCEND study (Telmisartan Randomized Assessment Study in ACE-I Intolerant Subjects with Cardiovascular Disease) evaluated the role of telmisartan in patients diagnosed with ischemic heart disease or diabetes with organ damage, who did not tolerate ACE inhibitors.